Bavarian Nordic to Present New Evidence for Mechanism of Action for PROSTVAC Immunotherapy at the 2014 ASCO Annual Meeting

| Source: Bavarian Nordic A/S
KVISTGAARD, Denmark, May 15, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
announced today a paper featuring the Company's lead cancer immunotherapy
candidate PROSTVAC® will be presented as a poster at the 2014 ASCO Annual
Meeting in Chicago, IL from May 30 to June 3. The presented work provides new
evidence elucidating the mechanism of action of PROSTVAC immunotherapy for
prostate cancer.

The abstract, "PROSTVAC, PSA-targeted Immunotherapy - New Evidence for Mechanism
of Action" will be presented during the General Poster Session, Developmental
Therapeutics: Immunotherapy, Sunday, June 1, 2014 from 8:00AM to 11:45 AM CDT.
The abstract can be seen at the ASCO Annual Meeting website:

Abstract Highlights:

  * Patients administered PROSTVAC immunotherapy showed evidence of significant
    enhancement of PSA-specific T cell responses compared to subjects
    administered placebo viral vectors.
  * Increased numbers and improved quality of activated PSA-specific T cells
    were observed with the PROSTVAC prime and boost regimen compared to single
    vector regimens in preclinical models.
  * The authors conclude that PROSTVAC immunotherapy elicits broad, highly
    functional T cell immunity to PSA, which then expands to include immune
    responses against endogenous tumor antigens not targeted by the
    immunotherapy, via antigen spreading.

"These data provide important new evidence supporting and elucidating the
increase in overall survival of men with metastatic, castrate-resistant prostate
cancer in our previously published Phase 2 study. PROSTVAC is now known to
elicit an initial PSA targeted immune response. The key subsequent event is a
broadened and personalized immune response against other tumor antigens through
a process of epitope or antigen spreading," said James B. Breitmeyer, President
of Bavarian Nordic's Cancer Immunotherapy Division.

Bavarian Nordic will also be present at the conference with an exhibit, booth
#2004 where attendees can learn more about PROSTVAC and the PROSPECT clinical
trial - a global, randomized, double-blind, placebo-controlled Phase 3 study of
PROSTVAC in men with asymptomatic and minimally symptomatic metastatic,
castration-resistant prostate cancer.

Bavarian Nordic will also host a PROSTVAC update and investor and analyst
reception on Saturday, May 31, 2014 in Chicago, IL at 5 PM CDT. Confirmed
speakers and panelists include Philip Kantoff, M.D. (Dana-Farber Cancer
Institute), James L. Gulley, M.D., Ph.D. (NCI), Ravi A. Madan, M.D. (NCI), Larry
Fong, M.D. (UCSF), Winald Gerritsen, M.D., Ph.D. (Radboud University Medical
Centre Nijmegen) and James B. Breitmeyer, M.D., Ph.D. (Bavarian Nordic). For
registration and more information on this event, visit http://www.bavarian-

Anders Hedegaard, President & CEO

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone
+45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.